JP2023139233A5 - - Google Patents

Download PDF

Info

Publication number
JP2023139233A5
JP2023139233A5 JP2023122283A JP2023122283A JP2023139233A5 JP 2023139233 A5 JP2023139233 A5 JP 2023139233A5 JP 2023122283 A JP2023122283 A JP 2023122283A JP 2023122283 A JP2023122283 A JP 2023122283A JP 2023139233 A5 JP2023139233 A5 JP 2023139233A5
Authority
JP
Japan
Prior art keywords
schizophrenia
pharmaceutically acceptable
solvate
hydrate
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023122283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023139233A (ja
Filing date
Publication date
Priority claimed from JP2020544729A external-priority patent/JP7355747B2/ja
Application filed filed Critical
Publication of JP2023139233A publication Critical patent/JP2023139233A/ja
Publication of JP2023139233A5 publication Critical patent/JP2023139233A5/ja
Priority to JP2025043078A priority Critical patent/JP2025090816A/ja
Pending legal-status Critical Current

Links

JP2023122283A 2017-11-14 2023-07-27 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 Pending JP2023139233A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025043078A JP2025090816A (ja) 2017-11-14 2025-03-18 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0151253 2017-11-14
KR20170151253 2017-11-14
JP2020544729A JP7355747B2 (ja) 2017-11-14 2018-11-13 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物
PCT/KR2018/013769 WO2019098634A1 (ko) 2017-11-14 2018-11-13 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020544729A Division JP7355747B2 (ja) 2017-11-14 2018-11-13 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025043078A Division JP2025090816A (ja) 2017-11-14 2025-03-18 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物

Publications (2)

Publication Number Publication Date
JP2023139233A JP2023139233A (ja) 2023-10-03
JP2023139233A5 true JP2023139233A5 (cg-RX-API-DMAC7.html) 2023-10-24

Family

ID=66539804

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544729A Active JP7355747B2 (ja) 2017-11-14 2018-11-13 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物
JP2023122283A Pending JP2023139233A (ja) 2017-11-14 2023-07-27 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物
JP2025043078A Pending JP2025090816A (ja) 2017-11-14 2025-03-18 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020544729A Active JP7355747B2 (ja) 2017-11-14 2018-11-13 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025043078A Pending JP2025090816A (ja) 2017-11-14 2025-03-18 カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物

Country Status (11)

Country Link
US (3) US11116751B2 (cg-RX-API-DMAC7.html)
EP (2) EP4545140A3 (cg-RX-API-DMAC7.html)
JP (3) JP7355747B2 (cg-RX-API-DMAC7.html)
KR (1) KR102739607B1 (cg-RX-API-DMAC7.html)
CN (2) CN117064892B (cg-RX-API-DMAC7.html)
AU (1) AU2018367733B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020009310A2 (cg-RX-API-DMAC7.html)
ES (1) ES3015458T3 (cg-RX-API-DMAC7.html)
IL (1) IL274437B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004975A (cg-RX-API-DMAC7.html)
WO (1) WO2019098634A1 (cg-RX-API-DMAC7.html)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2494109A1 (en) * 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
EP1809620B1 (en) * 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
AU2009348523B2 (en) 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
RU2610169C2 (ru) * 2014-09-11 2017-02-08 Общество С Ограниченной Ответственностью "Валентек" ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ
AU2015317877A1 (en) * 2014-09-15 2017-05-04 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
WO2016065586A1 (en) * 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole, triazole and tetrazole orexin receptor antagonists
US9771335B2 (en) 2015-07-31 2017-09-26 The Johns Hopkins University Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
US11221329B2 (en) * 2015-10-30 2022-01-11 Lieber Institute, Inc. Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
KR102900173B1 (ko) * 2016-12-14 2025-12-12 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Similar Documents

Publication Publication Date Title
JP2020023528A5 (cg-RX-API-DMAC7.html)
RU2445095C2 (ru) Новые фармацевтические композиции для лечения сексуальных расстройств
JP2018070614A5 (cg-RX-API-DMAC7.html)
CN101516840B (zh) 取代的n-酰基苯胺及其应用方法
CN106999462B (zh) 包含选择性s1p1受体激动剂的药物组合物
JP2019515884A5 (cg-RX-API-DMAC7.html)
US9884872B2 (en) Organic compounds
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
CN110169962B (zh) 用于治疗癌症的氧烯洛尔组合物
JP2024096962A (ja) ポネシモドを含有する医薬的組み合わせ
JP2020523317A5 (cg-RX-API-DMAC7.html)
RU2007112675A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ
JP2020502106A5 (cg-RX-API-DMAC7.html)
WO2022255790A1 (ko) 폐섬유화증의 예방 또는 치료용 약학 제제
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JP2019516722A5 (cg-RX-API-DMAC7.html)
CN101605541A (zh) 有效治疗化疗药物引起的周围神经毒性的吡咯并[1,2-a]咪唑二酮
CN119300818A (zh) 用于治疗癌症的包含metap2抑制剂的组合
JP2025529240A (ja) トリナパント、セダズリジン及びデシタビンによるt細胞リンパ腫の治療のための併用療法
JP2023549394A5 (cg-RX-API-DMAC7.html)
WO2024010030A1 (ja) 血中マイオスタチン低下剤
RU2020119301A (ru) Смесь, содержащая карбаматное соединение для предотвращения, облегчения или лечения шизофрении
US20250002512A1 (en) Novel anti-depressant and neuroplastic agents and therapeutic uses thereof